UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.397

Sortiert nach

Lung cancer: current therapies and new targeted treatments

The Lancet (British edition), 2017-01, Vol.389 (10066), p.299-311

2017

Link zum Volltext

Verfügbarkeit prüfen

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

The New England journal of medicine, 2014-12, Vol.371 (23), p.2167-2177

2014

Link zum Volltext

Verfügbarkeit prüfen

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Clinical cancer research, 2017-06, Vol.23 (12), p.3012-3024

2017

Link zum Volltext

Verfügbarkeit prüfen

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

The lancet oncology, 2017-11, Vol.18 (11), p.1454-1466

2017

Link zum Volltext

Verfügbarkeit prüfen

Emerging therapies for non-small cell lung cancer

Journal of hematology and oncology, 2019-04, Vol.12 (1), p.45-45, Article 45

2019

Link zum Volltext

Verfügbarkeit prüfen

Combination Therapy for EGFR -Mutated Lung Cancer

The New England journal of medicine, 2023-11, Vol.389 (21), p.2005-2007

2023

Link zum Volltext

Verfügbarkeit prüfen

Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study

International journal of cancer, 2021-05, Vol.148 (9), p.2313-2320

2021

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients

Nature communications, 2019-04, Vol.10 (1), p.1772-1772, Article 1772

2019

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

The New England journal of medicine, 2023-07, Vol.389 (2), p.137-147

2023

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

The New England journal of medicine, 2020-10, Vol.383 (18), p.1711-1723

2020

Link zum Volltext

Verfügbarkeit prüfen

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2022-04, Vol.40 (12), p.1301-1311

2022

Link zum Volltext

Verfügbarkeit prüfen

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-08, Vol.36 (22), p.2251-2258

2018

Link zum Volltext

Verfügbarkeit prüfen

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

The lancet oncology, 2020-07, Vol.21 (7), p.914-922

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

The lancet oncology, 2015-07, Vol.16 (7), p.830-838

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

Journal of clinical oncology, 2016-11, Vol.34 (31), p.3740-3748

2016

Link zum Volltext

Verfügbarkeit prüfen

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

The lancet oncology, 2015-02, Vol.16 (2), p.141-151

2015

Link zum Volltext

Verfügbarkeit prüfen

Trends in oncology drug innovation in China

Nature reviews. Drug discovery, 2021-01, Vol.20 (1), p.15-16

2021

Link zum Volltext

Verfügbarkeit prüfen

EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?

Trends in pharmacological sciences (Regular ed.), 2016-11, Vol.37 (11), p.887-903

2016

Link zum Volltext

Verfügbarkeit prüfen

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

The lancet oncology, 2018-01, Vol.19 (1), p.139-148

2018

Link zum Volltext

Verfügbarkeit prüfen

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR / ALK wild-type advanced non-small cell lung cancer

Journal for immunotherapy of cancer, 2020-01, Vol.8 (1), p.e000376

2020

Link zum Volltext

Verfügbarkeit prüfen

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Journal of clinical oncology, 2021-03, Vol.39 (7), p.713-722

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.397

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.208)
Mit Volltextzugriff
(1.322)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(821)
Life Sciences & Biomedicine
(641)
Humans
(480)
Oncology
(411)
Female
(275)
Male
(261)
Middle Aged
(224)
Lung Neoplasms - Drug Therapy
(217)
Lung Cancer
(209)
Aged
(195)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(185)
Mutation
(185)
Lung Neoplasms - Genetics
(184)
Adult
(179)
Respiratory System
(175)
Lung Neoplasms - Pathology
(154)
Carcinoma, Non-Small-Cell Lung - Genetics
(139)
Carcinoma, Non-Small-Cell Lung - Pathology
(109)
Technology
(100)
Chemotherapy
(98)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Lung cancer: current therapies and new targeted treatments

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Emerging therapies for non-small cell lung cancer

Combination Therapy for EGFR -Mutated Lung Cancer

Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Trends in oncology drug innovation in China

EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR / ALK wild-type advanced non-small cell lung cancer

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Suchergebnisse filtern